Literature DB >> 31736191

Identifying tests related to breast cancer care in claims data.

Benjamin L Franc1, Robert Thombley2, Yanting Luo2, W John Boscardin3, Hope S Rugo4, David Seidenwurm5, R Adams Dudley2.   

Abstract

To develop a method for calculating rates of testing for breast cancer recurrence in patients who have already undergone initial treatment for breast cancer, we calculated rates in a cohort of Medicare breast cancer patients and an age-matched noncancer cohort. We first used only tests with claims including diagnosis codes indicating invasive breast cancer and then used all tests regardless of diagnosis code. For each method, we calculated testing rates in the breast cancer cohort above the background rate in the noncancer population. The two methods provided similar estimates of testing prevalence and frequency, with exception of prevalence of CT.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; imaging utilization; surveillance epidemiology and end results; test utilization

Mesh:

Year:  2019        PMID: 31736191      PMCID: PMC7304302          DOI: 10.1111/tbj.13691

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  13 in total

1.  Clinical surveillance for early stage breast cancer: an analysis of claims data.

Authors:  M S Simon; M Stano; R K Severson; M S Hoff; D W Smith
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Contextualizing the use of oncologic imaging within treatment phases: imaging trends and modality preferences, 2000-2014.

Authors:  T P Copeland; J M Creasman; D J Seidenwurm; B L Franc
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

3.  Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population.

Authors:  Margaret L Crivello; Karen Ruth; Elin R Sigurdson; Brian L Egleston; Kathryn Evers; Yu-Ning Wong; Marcia Boraas; Richard J Bleicher
Journal:  Ann Surg Oncol       Date:  2012-08-10       Impact factor: 5.344

4.  Use of imaging and biomarker tests for posttreatment care of early-stage breast cancer survivors.

Authors:  Erin E Hahn; Ron D Hays; Katherine L Kahn; Mark S Litwin; Patricia A Ganz
Journal:  Cancer       Date:  2013-09-16       Impact factor: 6.860

5.  Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.

Authors:  Benjamin L Franc; Timothy P Copeland; Robert Thombley; Miran Park; Ben Marafino; Mitzi L Dean; W John Boscardin; Hope S Rugo; David Seidenwurm; Bhupinder Sharma; Stephen R Johnston; R Adams Dudley
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

6.  Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state.

Authors:  Laura S Gold; Diana S M Buist; Elizabeth T Loggers; Ruth Etzioni; Larry Kessler; Scott D Ramsey; Sean D Sullivan
Journal:  J Oncol Pract       Date:  2013-05-28       Impact factor: 3.840

7.  Health services utilisation in breast cancer survivors in Taiwan.

Authors:  Yong A Wang; An-Chen Feng; Patricia A Ganz
Journal:  Sci Rep       Date:  2014-12-12       Impact factor: 4.379

8.  Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.

Authors:  John N Primrose; Rafael Perera; Alastair Gray; Peter Rose; Alice Fuller; Andrea Corkhill; Steve George; David Mant
Journal:  JAMA       Date:  2014-01-15       Impact factor: 56.272

9.  Evaluating surveillance breast imaging and biopsy in older breast cancer survivors.

Authors:  Tracy Onega; Julie Weiss; Roberta Diflorio; Todd Mackenzie; Martha Goodrich; Steven Poplack
Journal:  Int J Breast Cancer       Date:  2012-10-14

10.  Increasing Receipt of High-Tech/High-Cost Imaging and Its Determinants in the Last Month of Taiwanese Patients With Metastatic Cancer, 2001-2010: A Retrospective Cohort Study.

Authors:  Tsang-Wu Liu; Yen-Ni Hung; Thomas C Soong; Siew Tzuh Tang
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.